Ferronordic has entered into an agreement to purchase Rudd Equipment Company, Inc.
Q3: EBITDA NOK 4m – soft but broadly in line with our NOK 5m 2025 ambitions kept, company needs larg...
Biovica has established a partnership agreement with Axlab (A/S) to commercialize the DiviTum in the...
Bolaget har tecknat en ny stororder inom AI-infrastruktur med en framstående kund inom fordonsindust...
Redeye endorses Inhalation Sciences’ order worth approximately SEK3.
Lönsamheten viker i kvartalet Omsättningen i kvartalet uppgick till 633 mkr vilket rensat för valuta...
Q3-resultatet indikerar stabilitet i verksamheten Nettoomsättningen sjönk med 4,1% till 173,3 mkr (1...
Mendus’s Q323 update was primarily focused on the clinical progression of its lead cancer vaccine, v...
Redeyes was again surprised by the magnitude of the volume decline in the third quarter.
Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and Q3 report.
Redeye provides a brief comment on the planned start of the phase II trial of Lipisense.
Investors House reported Q3 revenues of EUR 1.6m, 8% below our estimate.
The Q3 2023 results landed on the softer side and, in our view, Q4 may not bring clear relief just y...
Redeye saw a Q3 report that was both better and weaker than expected.
Redeye is making some small positive revisions to our forecasts and valuation following the Q3 repor...
Redeye retains its positive stance on Speqta following the Q3 report, as BrightBid continued its sol...
Weak North America behind Q3 miss, Q4 EBITA guided +25% y-o-y With 5% less employees vs year-end, vi...
Aktieanalytiker Mathias Carlson intervjuar VD Andreas Säfstrand efter publicerad Q3-rapport.
Redeye states that following a long streak of dissatisfactory sales, Neonode is now clearly re-direc...
Movinn A/S (“Movinn” or the “Company”) continued to demonstrate growth during the third quarter of 2...
